Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market, By Disease Type (Amnestic MCI, Non-Amnestic MCI), Treatment Type (Medications, Therapy), Route Of Administration (Oral, Parenteral, Others), Drug Type (Branded, Generics), Gender Type (Male, Female), Age Type (Child, Adult, Geriatric), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacy), Country (South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel, and Rest of Middle East and Africa) – Industry Trends & Forecast to 2029
Market Analysis and Insights: Middle East and Africa Mild Cognitive Impairment (MCI) Treatment Market
The mild cognitive impairment (MCI) treatment market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.4% in the forecast period of 2022 to 2029 and is expected to reach USD 3,981.49 thousand by 2029. Wide portfolio offered by major players and growing awareness of mild cognitive impairment is expected to act as driver for the market growth.
Mild cognitive impairment (MCI) is an early stage of memory loss or other cognitive ability loss (such as language or visual/spatial perception) in individuals who maintain the ability to perform most activities of daily living independently. MCI can develop for multiple reasons, and individuals living with MCI may develop dementia. MCI can be an early stage of the disease continuum for neurodegenerative diseases, including Alzheimer's. In some individuals, MCI reverts to normal cognition or remains stable.
Mild cognitive impairment (MCI) is characterized by impairment in a single cognitive domain, usually memory (amnestic MCI), or moderate impairment in several cognitive domains. The prevalence of MCI among individuals living in long-term care settings varies from 5% to 10% in many nursing homes to up to 30%. The most frequently encountered form of MCI is the amnestic type. Less common variants of MCI present with localized impairment of other cognitive domains such as executive dysfunction in Frontotemporal lobar degeneration (FTLD).
Major factors driving the growth of the global mild cognitive impairment (MCI) treatment market are an increase in the older patients population, ongoing research to find the perfect and effective cure is expected to drive the market's growth in the coming time. However, the high cost of therapies procedures and product-associated adverse risks may hamper the market growth.
The mild cognitive impairment (MCI) treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the Mild Cognitive Impairment (MCI) Treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Mild Cognitive Impairment (MCI) Treatment Market Scope and Market Size
The mild cognitive impairment (MCI) treatment market is segmented on basis of disease type, treatment type, route of administration, drug type, gender, age, distribution channel, and end users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- Based on disease type, the mild cognitive impairment (MCI) treatment market is segmented into amnestic MCI and non-amnestic MCI. In 2022, the amnestic MCI segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to the increase in the older population across the globe.
- Based on treatment type, the mild cognitive impairment (MCI) treatment market is segmented into medication and therapy. In 2022, the medication segment is expected to dominate the global mild cognitive impairment (MCI) treatment market due to its immediate and effective impact on MCI symptoms.
- Based on route of administration, the mild cognitive impairment (MCI) treatment market is segmented into oral and parenteral, and others. In 2022, the oral segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to the non-invasive, high patient compliance, convenience handling, and not requiring any specific sterile conditions.
- Based on drug type, the mild cognitive impairment (MCI) treatment market is segmented into branded and generics. In 2022, the generics segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to the cost-effectiveness compared to branded drugs.
- Based on gender, the mild cognitive impairment (MCI) treatment market is segmented into male and female. In 2022, the male segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to a surge in mental health complications observed in the male population.
- Based on age, the mild cognitive impairment (MCI) treatment market is segmented into child, adult, and geriatric. In 2022, the geriatric segment is expected to dominate the global mild cognitive impairment (MCI) treatment market is due to a surge in vulnerable older people population with the highest rate of increase in the Asian region.
- Based on end users, the mild cognitive impairment (MCI) treatment market is segmented into hospitals, specialty clinics, homecare, and others. In 2022, the hospital segment is expected to dominate the global mild cognitive impairment (MCI) treatment market due to increased awareness regarding better and more effective treatment during hospital stays.
- Based on distribution channel, the mild cognitive impairment (MCI) treatment market is segmented into hospital pharmacies, retail pharmacy. In 2022, the hospital pharmacy segment is expected to dominate the global mild cognitive impairment (MCI) treatment market due to increased interaction with certified prescribers and health professionals to use antipsychotic drugs and guaranteed payment.
Mild Cognitive Impairment (MCI) Treatment Market Country Level Analysis
The mild cognitive impairment (MCI) treatment market is analyzed and market size information is provided by the country, disease type, treatment type, route of administration, drug type, gender type, age, distribution channel, and end users as referenced above.
The countries covered in the mild cognitive impairment (MCI) treatment market report are the South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait and rest of Middle East and Africa.
South Africa is expected to dominate the mild cognitive impairment (MCI) treatment market due to the increasing geriatric population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing strategic activities by major market players to enhance the awareness for mild cognitive impairment (MCI) treatment, is boosting the market growth of mild cognitive impairment (MCI) treatment market.
The mild cognitive impairment (MCI) treatment market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.
Competitive Landscape and Mild Cognitive Impairment (MCI) Treatment Market Share Analysis
Mild cognitive impairment (MCI) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to mild cognitive impairment (MCI) treatment market.
Some of the major players operating in the mild cognitive impairment (MCI) treatment market are Pfizer Inc., F. Hoffman La Roche Ltd, Novartis AG, Accord UK Ltd, Dr. Reddy’s laboratories Ltd, Hikma Pharmaceuticals PLC, Viatris Inc., Eisai. Co. Ltd., Sun Pharmaceuticals ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt, AstraZeneca, Cipla Inc., Takeda Pharmaceutical Company Limited, Allergan Aesthetics, Lupin, Jubilant Pharmova Limited, Lannett, Aurobindo Pharma, UCB S.A., Belgium, and WOCKHARDT, among others.
For instance,
- In July 2021, FDA approved Biogen Aduhelm (aducanumab) to treat patients with Alzheimer’s disease using the Accelerated Approval pathway
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company footprints in the mild cognitive impairment (MCI) treatment market which also provides the benefit for organization’s profit growth.
SKU-